Leap Therapeutics Retained Earnings Total Equity Over Time
| LPTX Stock | USD 2.98 0.06 2.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Leap Therapeutics Performance and Leap Therapeutics Correlation. Leap |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Leap Therapeutics. If investors know Leap will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Leap Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.003 | Return On Assets (0.46) | Return On Equity (0.81) |
The market value of Leap Therapeutics is measured differently than its book value, which is the value of Leap that is recorded on the company's balance sheet. Investors also form their own opinion of Leap Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Leap Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Leap Therapeutics' market value can be influenced by many factors that don't directly affect Leap Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Leap Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Leap Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Leap Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Total Equity Analysis
Compare Leap Therapeutics and related stocks such as X4 Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Retained Earnings Total Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XFOR | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (194.2 M) | (376.7 M) | (376.7 M) | (339.1 M) | (356 M) |
| TERN | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (242.4 M) | (218.2 M) | (229.1 M) |
| DAWN | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (127.5 M) | (269.7 M) | (242.7 M) | (254.8 M) |
| PDSB | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (101.6 M) | (101.6 M) | (91.4 M) | (96 M) |
| INZY | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (91.1 M) | (147.7 M) | (214.8 M) | (193.3 M) | (202.9 M) |
| ELEV | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (150.3 M) | (135.2 M) | (142 M) |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| HEPA | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (104.1 M) | (175.7 M) | (175.7 M) | (158.1 M) | (166 M) |
| HOOK | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (147.1 M) | (222.8 M) | (287.7 M) | (258.9 M) | (271.9 M) |
| ABOS | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (127.6 M) | (170.4 M) | (153.4 M) | (161.1 M) |
Leap Therapeutics and related stocks such as X4 Pharmaceuticals, Terns Pharmaceuticals, and Day One Biopharmaceu Retained Earnings Total Equity description
The portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt.My Equities
My Current Equities and Potential Positions
| Leap Therapeutics | LPTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.98
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.